Mexico Pharmaceuticals & Healthcare Report Q3 2014

Apr 24, 2014 - Business Monitor International - 141 pages
Abstract Table of Contents Request Details Related
PRINT & SHARE
Although Mexico has made great efforts to improve its regulatory framework and create a more hospitable business environment to entice pharmaceutical companies, it is still hard for multinationals to fully materialise their commercial benefit due to the significant market share of generic drugs. We believe that generic drugs will be a key element of Mexico's healthcare modernisation. They are a very effective way in which the government can control public spending while trying to increase medicines coverage. However, in the long term, Mexico's improving private health insurance sector and potentially significant investment from the government will boost patented drug consumption in the country.

Headline Expenditure Projections
  • Pharmaceuticals: MXN187.4bn (USD14.7bn) in 2013 to MXN204.1bn (USD16.3bn) in 2014; +8.9% in local currency terms and +10.8% in US dollar terms. Forecast decreased from Q214 due to increasing generic competition.
  • Healthcare: MXN1,044.3bn (USD81.8bn) in 2013 to MXN1,139.8bn (USD90.8bn) in 2014; +9.1% in local currency terms and +11.0% in US dollar terms. Forecast increased from Q214 due to more optimistic macroeconomic forecasts.
Risk/Reward Rating

Mexico scores 60.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Rating (RRR), making it the fourth-most attractive pharmaceutical market in the region.

Key Trends And Developments

March
  • Mexico's Federal Commission for Protection Against Health Risks (COFEPRIS) signed an agreement to promote innovation, under which the registration approval timeline for new molecules will be reduced to 60 working days from the previous 360 days.
  • COFEPRIS changed its clinical research protocol to reduce the pre-approval time for clinical trials from three months to one month. COFEPRIS has also authorised the National Institutes of Health, as well as speciality hospitals, to assist its clinical trial evaluation process.
  • Indian drugmaker Lupin revealed its acquisition of a 100% equity stake in Laboratorios Grin (Grin), a leading Mexican pharmaceutical company specialising in branded ophthalmic products.
  • Genomma acquired a 50% interest in Marzam Commercial and Industrial Group for MXN600mn (USD45.15mn).
  • GlaxoSmithKline Mexico's vice president and general manager, Jose Alberto Pena, told a local media organisation that the company has accelerated product registration in Mexico since November 2012. February
  • Mexico's secretary of Health, Mercedes Juan Lopez, stated that the federal agency plans to reduce out-ofpocket spending on healthcare and improve the quality of service through Seguro Popular in Mexico. The Health secretary has also planned to reform Seguro Popular to address issues such as the fragmented healthcare system and inefficient use of resources in Mexico.
BMI Economic View: We forecast Mexican real GDP growth to accelerate from 1.5% in 2013 to 3.5% in 2014, amid an acceleration in household spending growth and an improvement in investment, bolstered by a successful reform drive in 2013. Exports will also pick up this year as US demand for manufacturing exports strengthens.

BMI Political View: The recent approval of an energy sector liberalisation bill in Mexico, while monumental for the economy's long-term growth prospects, will create an extremely challenging political environment for President Enrique Pena Nieto throughout the rest of his administration. Popular perceptions of energy sector reform remain highly divisive, and we expect social and political tensions to increase over the coming months.

Order This Report

EASY ORDERING
Once you’ve selected your preferred license option, hit ‘order now’ to complete the checkout process using any major credit card, check or wire/bank transfer.
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including Daily Alerts, monthly regional Insights, and in-depth quarterly Country Forecast Reports.